Working with the NHS
At Bristol-Myers Squibb, we recognise the significant challenges facing the NHS. The public rightly want fast access to high quality care at a time and place that is convenient to them.
At the same time, the global recession means budgets are increasingly constrained. The challenge for the NHS, therefore, is to meet these public expectations with tighter resources.
We believe our portfolio of existing and pipeline medicines can be part of the solution to these challenges. These new medicines will offer opportunities for the NHS to provide patients with better outcomes and better quality of life. Yet we also recognise that new treatments will present challenges to the NHS.
New medicines often increase the upfront cost of healthcare. They may also require staff training, new capacity or changes to patient pathways. At a time when resources are stretched it is ever more important that the NHS gets the most out of the new medicines it invests in, in terms of both clinical outcomes and patient experience.
In recognition of this, our approach at Bristol-Myers Squibb is to work in partnership with the NHS to make sure it gets maximum value from our medicines.
Our teams are becoming more flexible when it comes to meeting customer needs rather than trying to apply a one-size-fits-all solution. In fact, we are now regularly having conversations with payers about providing a whole service and not just medicines.
Partnerships that bring value to the NHS
In order to meet its chosen strategy, every partnership entered into by Bristol-Myers Squibb with the NHS must be underpinned by four key undertakings:
- Bristol-Myers Squibb endeavours to continually develop medicines to meet true unmet medical need across a range of disease areas
- We are committed to enhancing clinical excellence through clinical research activities
- We will provide robust evidence on our medicines to support NHS decision makers
- Bristol-Myers Squibb is striving to improve its service delivery so that its medicines reach the right patients at the right time.
NHS Joint Working
Adverse Event Pathway Project (AEPP): Early recognition and rapid treatment of immune-related adverse events (IrAE) Joint Working Project; HEY NHS Trust and Bristol-Myers Squibb (2017)
Reducing Time to Treatment Administration (RTTA) Joint Working Project: Newcastle (NuTH) and Bristol-Myers Squibb (2017)
Immuno-Oncology (I-O) pathway configuration project (IPC project): Velindre NHS Trust (VCC) & Bristol-Myers Squibb (2017)
Adverse Event Pathway Project (AEPP): Early recognition and rapid treatment of immune-related adverse events: UCLH (on behalf of the Cancer Vanguard) and Bristol-Myers Squibb (2017)
Date of preparation: May 2018; MLTUK1701479-06